These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37647139)

  • 1. Adherence to Hormonal Therapies in Prostate Cancer.
    Hafron J; Sangha P; Kung T; Pruett J
    Urol Pract; 2023 Nov; 10(6):540-546. PubMed ID: 37647139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
    Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
    Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
    Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.
    Tatenuma T; Miyamoto H
    Drug Des Devel Ther; 2023; 17():2325-2333. PubMed ID: 37559910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.
    Kasparian S; Wei O; Tsai NC; Palmer J; Pal S; Lyou Y; Dorff T
    Oncologist; 2023 Aug; 28(8):699-705. PubMed ID: 36888587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
    Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
    George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
    Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relugolix: A Review in Advanced Prostate Cancer.
    Shirley M
    Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
    Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
    Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relugolix in the management of prostate cancer.
    Sahu KK; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
    Crawford ED; Twardowski PW; Concepcion RS; Hafron JM; Harris RG; Moul JW; Gordan LN; Petrylak DP; Atkinson SN; Boldt-Houle DM; Keane TE; Higano CS; Henderson RJ; Kader AK; Hussain MH; Shore ND
    J Urol; 2020 Apr; 203(4):743-750. PubMed ID: 31580749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.
    Adekunle OA; Seoane-Vazquez E; Brown LM
    J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
    Shore ND; Mehlhaff BA; Cookson MS; Saltzstein DR; Tutrone R; Brown B; Lu S; Fallick M; Hanson S; Saad F
    Adv Ther; 2023 Nov; 40(11):4919-4927. PubMed ID: 37713020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
    Gulley JL; Aragon-Ching JB; Steinberg SM; Hussain MH; Sartor O; Higano CS; Petrylak DP; Chatta GS; Arlen PM; Figg WD; Dahut WL
    J Urol; 2008 Oct; 180(4):1432-7; discussion 1437. PubMed ID: 18710748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade].
    Vojinov S; Levakov I; Jeremić D; Zivojinov S; Marusić G
    Vojnosanit Pregl; 2011 Apr; 68(4):321-6. PubMed ID: 21630520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.